Julian Klein

Julian Klein is an associate in the Governmental Practice in the firm's New York office.

Areas of Practice

Julian provides counseling on complex legal, regulatory, and compliance matters, working primarily with life sciences companies such as pharmaceutical and medical device manufacturers. He also assists companies in the financial sector—including asset management firms, investment banks, and hedge fund advisors—in navigating state and federal regulations.

In addition, Julian represents individuals and corporations in criminal investigations led by state and federal agencies, conducts internal investigations, and supports clients through both criminal and civil litigation.

Pro Bono

Julian has a strong commitment to Pro Bono work and assists in federal criminal defense through the Criminal Justice Act Panel.

Beyond his work in criminal defense, Julian is dedicated to advancing animal welfare and environmental protection through legal advocacy.

Professional and Educational Background

Prior to joining the firm, Julian attended St. John’s School of Law, where he graduate cum laude and served as an Associate Managing Editor for the St. John’s Law Review. Before law school, Julian earned his Bachelor’s Degree in Biology from Syracuse University and a Master’s Degree in Biomedical Sciences from Rutgers University. While at Rutgers, he conducted neurobiology research.

Articles

FDA Law Blog Posts

• "FDA’s Wave of Untitled Letters Signals Stricter Scrutiny for DTC Pharma Ads," October 1, 2025
• "FDA Unleashes Wave of Enforcement: The Industry Faces a Crackdown on Drug Advertising," September 19, 2025

• "FDA Ratchets Enforcement on Social Media Promotion in New Warning Letter," June 11, 2025
• "Onshoring Pharma Ops: Reading Recent EO and Policy Tea Leaves," May 9, 2025
• "Reminder: FDA Does, In Fact, Review DOF," March 11, 2025
• "Finally, FDA’s Final Word on Unapproved Use Communications," February 7, 2025
• "FDA Dumps Trio of Device-Related Guidances Prior to Administration Change," January 27, 2025
• "FDA Furthers Efforts to Improve the Accelerated Approval Pathway through New Draft Guidance on Confirmatory Trials," January 14, 2025
• "New Accelerated Approval Guidance Underscores Need for Accountability," December 19, 2024
• "Key Takeaways from FDA’s Latest Social Media Warnings," December 5, 2024